Compare · CODX vs SYK
CODX vs SYK
Side-by-side comparison of Co-Diagnostics Inc. (CODX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CODX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.44B, about 4905.2x CODX ($22.9M).
- Over the past year, CODX is down 38.7% and SYK is down 22.8% - SYK leads by 15.9 points.
- CODX has been more active in the news (19 items in the past 4 weeks vs 10 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 3 for CODX).
- Company
- Co-Diagnostics Inc.
- Stryker Corporation
- Price
- $5.28-15.65%
- $294.29+0.28%
- Market cap
- $22.9M
- $112.44B
- 1M return
- +232.08%
- +1.12%
- 1Y return
- -38.68%
- -22.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 19
- 10
- Recent ratings
- 3
- 25
Co-Diagnostics Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CODX
- Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
- SEC Form EFFECT filed by Co-Diagnostics Inc.
- SEC Form S-3 filed by Co-Diagnostics Inc.
- Chief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes
- President Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)
- Director Murphy Edward L. was granted 1,695 shares, increasing direct ownership by 18% to 11,084 units (SEC Form 4)
- Director Serbin Richard S was granted 1,695 shares, increasing direct ownership by 19% to 10,751 units (SEC Form 4)
- Director Durenard Eugene was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)
- Director Nelson James B was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation